Tamoxifen is currently the most widely used drug for the treatment of breast cancer, but there now exists considerable evidence that tamoxifen can also induce endometrial hyperplasia in pre menopausal women. We have used PCR dierential display on primary human endometrial isolates in an attempt to identify genes induced by tamoxifen but not estrogen. Eight such dierentially expressed bands were cloned and sequenced, one of which was found to be the peptide adrenomedullin. We have shown that adrenomedullin is a novel growth factor for endothelial cells and is angiogenic in vivo in the chick chorioallantoic membrane assay. Immunohistochemical analysis of endometrial sections have shown that while macrophages in the endometrium express adrenomedullin at a low level, endometrial macrophages of women receiving tamoxifen strongly express adrenomedullin (P=0.008). We postulate that endometrial induction of the angiogenic factor adrenomedullin by tamoxifen is part of the mechanism by which tamoxifen results in endometrial hyperplasia.
Introduction
Tamoxifen, a nonsteroidal antioestrogen, is currently the long term endocrine treatment of choice for selected patients with breast cancer since large clinical trials have demonstrated reduction in recurrence and overall survival bene®t. It is currently being evaluated as a chemopreventive agent in young healthy women at high risk for breast cancer (Powles et al., 1990; Nay®eld et al., 1991) . One of the most signi®cant complications of long term tamoxifen use is the development of endometrial cancer with up to a 7.5-fold increase in risk (Barakat, 1996; Fisher et al., 1994; Rutqvist et al., 1995) . Tamoxifen treatment has also been implicated in the development of endometrial polyps and endometrial hyperplasia (Gal et al., 1991; Lahti et al., 1993; Kedar et al., 1994) . The polyps are unusually large and show proliferative changes, aberrant epithelial dierentiation and focal periglandular stromal condensation (Ismail, 1994) . In addition, women taking tamoxifen have been found to have a signi®cantly larger uterine volume with a lower impedance to blood¯ow in the uterine arteries (Kedar et al., 1994) .
Tamoxifen, in addition to having anti-oestrogenic, also has oestrogenic activity which is thought to be responsible for its adverse uterine eects. The ®rst observation that tamoxifen may have adverse eects on the endometrium was when it was found to increase uterine weight in immature female rats (Harper and Walpole, 1967) . Tamoxifen has been shown to stimulate growth of endometrial carcinoma lines in both in vivo and in vitro systems (Jordan et al., 1991) . The mechanism by which tamoxifen has a partial agonist eect has received considerable attention, particularly in studies of oestrogen receptor function and transcriptional control. Thus, studies of a series of human oestrogen receptor mutants to evaluate the cell and promoter speci®c transcriptional activities of the TAF1 and TAF2 transactivation regions, indicate that tamoxifen is both a cell type and promoter context speci®c oestrogen receptor partial agonist (Berry et al., 1990; Tzukerman et al., 1994) . Recently an alternative pathway of oestrogen receptor action has been reported in which the receptor appears to be able to stimulate transcription via an activator protein-1 (AP-1) directed pathway rather than via classical oestrogen response elements. Thus, tamoxifen was found to be a potent activator of ER mediated induction of promoters regulated by AP-1 sites in a cell type speci®c pattern; with agonism only occurring in cell lines of uterine but not of breast origin (Webb et al., 1995) . Alternatively tamoxifen may act by an oestrogen independent mechanism as has been proposed for its stimulation of TGFb in vitro in human fetal ®broblasts and in vivo in human breast tissue stroma (Colletta et al., 1990; Butta et al., 1992) .
Tamoxifen modulates uterine expression of at least two peptide growth factor systems. It stimulates insulin like growth factor-1 and inhibits insulin like growth factor binding protein-3 expression in the rat uterus (Huyhn and Pollack, 1994) . Tamoxifen stimulates transforming growth factor b-1 and transforming growth factor b-2 expression in rat uterine stromal cells (Sartor et al., 1995) . With regard to oncogenes, in rat endometrium tamoxifen induces persistent over expression of c-fos and jun-B in epithelial cells; c-jun is stimulated to a lesser extent in stromal but not epithelial cells; while jun-D is transiently stimulated in epithelial cells (Nephew et al., 1996) . Expression of c-fos in human endometrial carcinoma transplanted into mice is increased by tamoxifen (Sakakibura et al., 1992). Members of the Fos and Jun families can dimerise and control expression of many target genes through AP-1 elements (Angel and Karim, 1991) . In this context the recent studies demonstrating that tamoxifen targets AP-1 sites, and the AP-1 proteins such as Jun or Jun/Fos are needed for stimulation in uterine cell lines is of interest (Webb et al., 1995) .
The objective of the present study was to examine gene expression in isolated normal human endometrial cells in response to tamoxifen in vitro, using PCR dierential display and cDNA library screening techniques. Our results show for the ®rst time that tamoxifen induces adrenomedullin, a vasoactive peptide, ®rst detected in a human adrenal phaeochromocytoma by monitoring of its stimulation of platelet cAMP production (Kitamura et al., 1993) . Adrenomedullin immunoreactivity and mRNA are widely distributed in human and rat tissues including heart, aorta and lung, and the peptide is present in plasma (Ichiki et al., 1994) . Ours is the ®rst report of the presence of adrenomedullin in human endometrium. The peptide contains 52 amino acids and shares some homology with calcitonin gene related peptide. We also report for the ®rst time its angiogenic activity in the chicken chorioallantoic membrane assay and its expression in the endometrium of women that had received tamoxifen.
Results

Identi®cation of adrenomedullin induction in endometrial stromal cells
Dierential PCR display was employed to analyse the gene expression patterns of endometrial stromal cells that had been treated with either tamoxifen or oestrogen. From 12 dierent combination PCR reactions with ®ve random 10 mer 5' primers and three sets of anchored primers, eight bands larger than 250 bp were reproducibly detected in the tamoxifen treated cells, when compared to control or oestrogen treated cells (Figure 1 ). One out of eight fragments was found to comprise a correct anchored primer, while the rest of the bands contained 10 mer primers on both 5' and 3' of their sequence. All sequences were compared with those present in the EMBL data library. The PCR fragments having 10 mers at both ends with a low percentage homology to known mRNA sequences were not investigated further. The fragment having the anchored primer was identi®ed as the peptide adrenomedullin. RNAse protection analysis was performed with the dierentially expressed fragment on RNA isolated from endometrial stromal cells. The dierentially expressed mRNA was 2.5 ± 3-fold greater in the tamoxifen treated cells than in the 17b oestradiol treated or control cells ( Figure 2) ; one of the ®ve isolates having a lower level of expression than the other four.
Endothelial growth factor and angiogenic activity of adrenomedullin
The response of HUVEC's to adrenomedullin in the range of 10 78 M to 10 710 M, revealed that a maximal stimulation of cell growth occurred when cells were supplemented with 10 78 M adrenomedullin ( Figure 3 ) bFGF was used as a positive control.
Adrenomedullin was also angiogenic in the chick chorioallantoic membrane assay. After 72 h of incubation in the presence of adrenomedullin vascular remodelling ( Figure 4 ) and growth occurred maximally in the presence of 10 710 M adrenomedullin ( Figure 5 ).
Immunohistochemical localisation of adrenomedullin in human endometrium
Endometrial sections stained with an antibody to adrenomedullin were scored on a scale of 1 ± 3 + , with T E C Differential band Figure 1 Induction of an unidenti®ed gene in normal endometrial stromal cells on 12 h exposure to 10 mm tamoxifen but not oestrogen. T=tamoxifen; E=oestrogen; C=control 3 + indicating a strong positive result, the stromal, macrophage and epithelial component of the endometrium was reviewed. In all instances sections were scored by two independent reviewers. Staining was performed on endometrial tissue from a number of distinct patient groups, including pre (n=30) and post (n=10) menopausal, normal endometrial tissue and pre (n=11) and post (n=17) menopausal tissue from women receiving tamoxifen for the treatment of breast cancer ( Figure 6 ). Both the stromal and epithelial components of the endometrium stained positive for adrenomedullin ( Figure 6a ), with the highest degree of staining corresponding to macrophages present in the stroma (Figure 6b ). Immunohistochemical staining of pre menopausal endometrium, from women not previously exposed to tamoxifen showed a very low level of adrenomedullin expression (Figure 6c ).
The immunohistochemical staining results from the various subsets of patients were analysed by a Chisquared test, with a P value of 50.05 taken to indicate a signi®cant dierence between the subsets being compared.
Signi®cantly increased staining for ADM in the macrophages was found in the endometrium in tamoxifen vs non tamoxifen treated women (P=0.0015) irrespective of age and menopausal status. In endometrial polyps, macrophage staining for adrenomedullin was signi®cantly greater than in normal tissue (P=0.0015) irrespective of age, menopausal status and tamoxifen exposure. In the CD68 negative stromal cell population adrenomedullin expression in the tamoxifen exposed tissue was signi®cantly higher (P=0.0081) than in the non exposed tamoxifen tissue, only in samples obtained from pre menopausal women. No dierence in the epithelial expression of adrenomedullin was found between the tamoxifen and non tamoxifen exposed groups in either pre or post menopasual women. The distribution of macrophages in both non tamoxifen treated and tamoxifen treated endometrium was further investigated by immunohistochemistry with an antibody to CD68 (results not shown). This indicated macrophages were widely distributed in the stroma of the endometrium, irrespective of menstrual status, the presence or absence of polyps and tamoxifen treatment. Further to this it was revealed by comparison of the CD68 staining to the adrenomedullin staining that non polyploidal areas of the endometrium contained macrophages of which only a limited number stained positive for the production of adrenomedullin. However the proportion of macrophages present in polyploidal areas, staining for adrenomedullin increased distinctly, this was true irrespective of whether the tissue had been exposed to tamoxifen.
Discussion
We have demonstrated for the ®rst time induction of adrenomedullin by tamoxifen in human endometrium and further that adrenomedullin is an endothelial cell growth factor and is angiogenic. It is therefore a potential key player in the endometrial response to tamoxifen. Long term adjuvant tamoxifen therapy has proven eectiveness in enhanced survival of breast cancer patients. The increasing use of tamoxifen as a chemopreventative agent in healthy women makes it essential to improve our understanding of the mechanism by which tamoxifen mediates the increased prevalence of polyps, hyperplasia and carcinoma in Figure 5 Angiogenic response of the chick chorioallantoic membrane assay to adrenomedullin *=P50.05, **=P50.005 Our results demonstrate by the technique of PCR display that the treatment of pure cultures of endometrial stromal cells with tamoxifen in vitro induces adrenomedullin. This response does not occur on treatment of the stromal cell cultures with oestrogen. Examination of adrenomedullin expression in intact tissue was by immunohistochemistry, where both the stromal and epithelial component of the endometrium express adrenomedullin. Of speci®c interest is the strong staining of macrophages present in the stroma of the endometrium, indicating the localised production of adrenomedullin by macrophages, which may have a speci®c action in mediating the eects of tamoxifen on the endometrium. This observation coupled to the higher proportion of adrenomedullin expressing macrophages present in polyploidal areas as compared to non polyploidal endometrium suggests adrenomedullin may stimulate the formation and growth of polyps within the endometrium.
The observation in Swiss 3T3 cells (Withers et al., 1996) that adrenomedullin is capable of acting as a potent mitogen together with the above data, showing that adrenomedullin is able to mediate the growth of endothelial cells is consistent with an involvement in tamoxifen mediated hyperplasia, the development of polyps and the possibility of neoplastic change. Additionally the observation that adrenomedullin is expressed in a number of human tumors of both pulmonary and neural lineage, including small cell lung carcinoma, adenocarcinoma, bronchoalveolar carcinoma, lung carcinoids ganglioblastoma and neuroblastoma (Martinez et al., 1995; Satoh et al., 1995) raises the possibility that in addition to endometrial carcinoma, polyps and hyperplasia adrenomedullin may be involved in the formation and or growth of tumors and indeed it has been demonstrated by blocking the biological activity of adrenomedullin, by the use of a monoclonal antibody in neoplastic cell lines that tumor growth is signi®cantly suppressed .
The eects of tamoxifen on the uterus may be further compounded by the known ability of adrenomedullin to lower the impedence of blood¯ow (Kitamura et al., 1993 ). An increased blood¯ow may have a role in human pregnancy, as adrenomedullin is known to be expressed in both amniotic¯uid and the epithelium of the human amnion, where it is possible it regulates fetal and maternal blood pressure (Macri et al., 1996) . It has recently been shown that HUVEC themselves secrete adrenomedullin in addition to having the adrenomedullin receptor and clearly an autocrine growth loop operates (Ishihara et al., 1997) .
The mechanism of action by which tamoxifen stimulates the adrenomedullin gene is presently unknown, although analysis of the upstream sequence of the adrenomedullin gene reveals the presence of a number of promoters. Of particular interest with respect to tamoxifen induced gene expression is the presence of two AP1 binding sites at position 71549 and 71801 respectively (Ishimitsu et al., 1994) , as it has been demonstrated that tamoxifen is able to initiate gene transcription via an AP-1 site (Webb et al., 1995) . In conclusion adrenomedullin has the potential to be a mediator for the proliferative and vascular eects of tamoxifen on the uterus. Further experiments are required to examine the precise mechanism of action by which tamoxifen stimulates adrenomedullin.
Materials and methods
Culture of human endometrial cells
Primary endometrial stromal cells were isolated from human uteri as described (Zhang et al., 1995) . The cells were cultured in Dulbecco's minimal essential medium (DMEM, Gibco) at 378C in 5% CO 2 and 10% fetal calf serum (FCS, Gibco) to 80% con¯uence. Cells were then washed 62 with PBS and cultured for 10 days in phenol red free DMEM containing 10% FCS, cells were then left to grow overnight either in a phenol red free medium or that supplemented with 10 76 M tamoxifen (Sigma) or 10 710 M 17-b oestradiol (Sigma), before having the RNA extracted.
RNA preparation
Total cellular RNA was isolated by the guanidine isothiocyanate/caesium chloride method (Maniatis, 1982) . The cells were washed twice with PBS and lysed in a 4 M guanidium isothiocyanate solution. Genomic DNA was sheared using a syringe with a 20-G needle. Total RNA was recovered by centrifugation at 50 k r.p.m. on a 5.7 M CsCl gradient. A trace of genomic DNA was removed by incubation of the total RNA at 378C for 30 min with DNase I (BRL) in the presence of a human placental ribonuclease inhibitor (BRL). Protein was extracted with phenol/chloroform. Puri®ed RNA was concentrated by ethanol precipitation. The total RNA was then enriched for poly(A) RNA by using a poly(A) quick mRNA isolation kit (Strategene).
Dierential PCR display
Reverse transcription was carried out in the three independent reactions using anchored Oligo (dT) primers, i.e. T 11 VC, T 11 VG or T 11 VT[V=A,C or G] as described by Liang and Pardee (1992) . Poly(A) RNA (0.5 mg) was heated to 658C for 10 min in the presence of 20 mM anchor primers. After cooling on ice, 25 mM dNTP's, 10 U RNAsin, 10 mM DTT, 16reverse transcription buer and 300 U MMLV reverse transcriptase [invitrogen] were added to a total volume of 50 ml. The reaction was incubated at 378C for 90 min and stopped by incubation at 958C for 5 min.
Ampli®cation of cDNA by PCR Dierential PCR display was performed following the method described by Liang and Pardee (1992) . Five 10 mer deoxyoligonucleotide primers with arbitrary sequences [5'-TGCTTGGACT-3', 5'-GTTI-CAGCTC-3', 5'-TACAACGAGC-3', 5'-AGC-CAGCGAA-3') were synthesised (ICRF). PCR mixture was prepared in a 0.5 ml Eppendor containing 5 mM of the corresponding anchor primer, 0.5 mM of a 10 mer primer, 2 mM dNTPs, 5 mCi[
39 P]dATP, PCR buer and 1 U Taq polymerase (Boehringer Mannheim). Incubation was performed for ®ve cycles under the following consecutive conditions: 948C for 30 s, 358C for 30 s, 428C for 1 min and 728C for 1 min, followed by an additional extension at 728C for 5 min.
Dierential display of DNA fragments The ampli®ed cDNA was denatured by the addition of 5 ml of denaturing loading buer (80% formamide, 0.25% bromophenol blue, 0.25% xylene cyanol) to 5 ml of the Induction of adrenomedullin by tamoxifen Y Zhao et al PCR mixture, which was then heated at 958 for 2 min. The denatured specimens were resolved on a 6% polyacrylamide/urea gel in TBE buer at 80W. DNA was transferred to 3 MM ®lter paper and dried in a vacuum drying system before being exposed to X-ray ®lm at 7708C overnight.
Ampli®cation, cloning and sequencing of dierentially expressed cDNA fragments Dierentially expressed cDNA fragments were excised from the gel, rehydrated in boiling water for 15 min, and ethanol precipitated at 7708C for 2 h to remove contaminants. The recovered DNA was reampli®ed in the presence of the corresponding anchor OligodT and 10 mer primers under the same conditions as for the primary PCR reaction. Reampli®cation products were visualized on a 1% agarose gel and puri®ed with a GeneClean kit (Bio 101). The reampli®ed cDNA was cloned into a plasmid using a pGEM-T vector system (Promega). DNA inserts were then sequenced with a T7 sequencing kit (Amersham). One out of eight fragments was found to comprise a correct anchored primer (Figure 2 ), while the rest of the bands contained 10 mer primers on both 5' and 3' ends of their sequence. All the sequences were compared with those present in the EMBL data library.
Identi®cation of a full length cDNA by screening a cDNA library
Construction of a cDNA library from human endometrial stromal cells Three expression libraries were constructed using cDNAs from primary cultured endometrial stromal cells treated with or without tamoxifen or 17b oestradiol. Construction was performed with a copy kit (cDNA synthesis system, Invitrogen).
Brie¯y, reverse transcription was directed using a Oligo dT (NotI) unidirectional primer (Invitrogen) to generate cDNA containing a NotI site on the 3' end. 5' blunt-ended cDNA was added with adapter BstXI cDNA was size-fractionated on 1% agarose gel and enriched by the removal of smaller size of cDNAs (5500 bp). The enriched cDNA was digested with NotI before being cloned into a pcDNA 1 neo, vector (Invitrogen). The libraries contained 8610 5 to 2610 6 colonies with an insert size of up to 7 kb.
Screening of the cDNA library The initial pool of a tamoxifen treated cDNA library was plated onto LB agar plates with 5610 5 colonies to be screened. A dierentially expressed cDNA fragment with a correct anchor and 10 mer primer sequence was labelled with [ 32 P]ATP by using a prime-a-gene system (Promega) and was used to hybridize the cDNA library. After two rounds of screening, 25 positive colonies were analysed by enzyme digestion and were then sequenced using an ABI automated sequencer. Ten primers were synthesized (ICRF) to sequence the full length of cDNA on both strands. Sequence homologies with existing sequences were determined using the GCG software package (University of Wisconsin).
RNase protection analysis
Stromal cells were isolated from ®ve individual women for this part of the study and were treated with or without tamoxifen or 17b oestradiol. RNase protection assay was performed following the protocols described by Ausubel et al. (1990) . Brie¯y, total RNA extracted from the cells was denatured and hybridized with 32 P-labelled cDNA and GAPDH as a loading control. Incorporated single strand RNA was digested with RNase H (Promega). The protected fragments were size-fractionated on a 6% polyacrylamide gel and autoradiographed as described.
Immunohistochemical analysis of endometrial tissue
Archival specimens of endometrium were examined where tissue had been removed at either endometrial biopsy or hysterectomy (Department of Histopathology, John Radclie Hospital, Oxford). The categories of endometrium examined were: (i) normal endometrium throughout the menstrual cycle; (ii) endometrium exposed to tamoxifen with no pathological abnormality; (iii) endometrium exposed to tamoxifen with, polyps or carcinoma; and (iv) post menopausal normal endometrium. Endometrial tissue was ®xed in 10% buered formalin, prior to being embedded in paran. 6 mm sections were cut and mounted on silica treated glass slides. The slides were incubated at 608C and deparanized in Citroclear (HD supplies Burks), before being ®xed in ethanol. After a ®nal wash the slides were incubated with 5% goat serum (Dako) to reduce non speci®c background staining and were then incubated in humidi®ed chambers for 24 h at 48C with rabbit polyclonal anti-adrenomedullin antiserum (Peninsula, Warrington) at a dilution of 1 : 800. Throughout the staining protocol both a positive control of human heart or kidney and a negative control of endometrial tissue incubated with Rabbit IgG in the place of primary adrenomedullin antibody were included. All slides were incubated for 30 min with a second biotinylated swine antirabbit antibody (Dako) at a dilution of 1 : 400 after which the slides were incubated with streptoavidin 1 : 200 (Dako) for 30 min, the ®nal colour being developed with new fuschin kit (Dako). The immunohistochemical staining from the various subsets of patients was compared by means of a Chi squared test, with Yates correction being performed were the individual sample groups fell below 5.
In order to determine the relative proportion of macrophages which stain positive for adrenomedullin in the endometrium, the overall presence of macrophages was determined using Dako KP-1 (Dako) which recognizes CD68. The slides were deparanized and ®xed as before, followed by 10 min trypsin pretreatment (Jones et al., 1996) . Sections were then blocked in a 1 : 10 solution of rabbit serum (Dako) in TBS to block non speci®c binding sites. After 10 min excess serum was removed and the sections were incubated overnight with the KP-1 primary antibody (Dako) in humidi®ed chambers. After washing in TBS the sections were incubated at room temperature for 30 min with a biotinylated rabbit anti-mouse immunoglobulin (Dako) diluted 1 : 500 in TBS, washed twice in TBS and incubated for a further 30 min in Streptavidin (Dako) 1 : 200 in TBS. Again the ®nal colour was developed with the New fushin kit (Dako).
Endothelial cell growth curves
Human umbilical vein endothelial cells (HUVECs) were isolated by collagenase digest of fresh umbilical veins (Jae et al., 1973) . Cells were seeded into gelatin coated six well plates in 10% FCS/DMEM at a density of 1500 cells per well.
Cultures were left for 24 h and then treated with fresh 10% FCS/DMEM, containing concentrations of adrenomedullin ranging from 10 77 M to 10 79 M. Every 48 h over a period of 6 days cells in speci®c wells were subjected to trypsin digest and cell number determined in a Coulter counter. A positive control of 10 ng/ml bFGF and a negative control of unsupplemented 10% FCS/DMEM media were included throughout the assay.
Chick chorioallantoic membrane assay
The CAM assay was based on a modi®ed method of Peek et al. (1988) . While fertilised eggs were obtained locally and incubated at 378C and 60% relative humidity in an Octagon 100 egg incubator (Brinsea Products Ltd, Sanford, UK) with automatic rotation every 30 min for 8 days. On day 9, the embryonic blood vessels and air sac were identi®ed by illumination with a candling lamp. A small hole of approximately 1 mm61 mm over the air sac was ground down ®rst using a micro-portable dentists drill (Cottrell & Company, Swansea, UK) . A second window approximately 2 mm62 mm was cut on the broad side of the egg directly over the embryonic blood vessels, as determined by candling. All trace of shell dust on the egg surface was removed. A window was created by gently lifting one corner of the cut egg shell using a pair of ®ne tipped forceps, the window was then enlarged to approximately 10 mm610 mm over the CAM.
A sterile methylcellulose disk containing adrenomedullin was placed on the CAM in a site not directly over or immediately next to large vessels in order to avoid a counting bias resulting from large diameter vessels in the area analysed. The exposed windows were covered with a piece of para®lm soaked in 70% ethanol. The eggs were continually incubated without rotation until day 12. The angiogenic response was scored as previously described by Vu et al. (1984) without knowledge of the experimental group.
Following scoring, 0.5 ml of a 1% solution of sodium nitroprusside (Sigma) in PBSA was immediately applied to the upper surface of the exposed chorioallantoic membrane for 2 min to ensure that the vessels on the chorioallantoic membrane were dilated and ®lled with blood. The chorioallantoic membrane was then ®xed with 1.5 ml of 10% buered formalin for 10 min and then excised as closely as possible to the shell and stored in buered formalin.
Quantitation of the vascular density, represented by an area percentage (AREAP) was obtained to estimate the chorioallantoic membrane vascularity using a morphometric/ colourimetric analysis. This was performed using a Roche Pathology Workstation (RPW) with an Optronics low light single chip video camera running Vidas 2.5 software.
